Trial Profile
A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs MAX-40279 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Maxinovel Pharmaceuticals
- 18 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 18 Jan 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2022.
- 20 May 2021 Planned End Date changed from 1 May 2021 to 1 Dec 2021.